Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cybin ( (TSE:CYBN) ) just unveiled an announcement.
On December 18, 2025, Cybin Inc. announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market, with trading on NYSE American expected to cease at the close of January 2, 2026 and Nasdaq trading to begin on January 5, 2026. Concurrent with the Nasdaq debut, the company will begin doing business as Helus Pharma and change its U.S. and Cboe Canada ticker symbol from “CYBN” to “HELP,” moves that management positions as a key step in Cybin’s evolution into a global pharmaceutical player and that are likely aimed at boosting visibility and alignment with the larger community of Nasdaq-listed drug developers.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$55.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc., soon to be doing business as Helus Pharma, is a clinical-stage pharmaceutical company focused on revolutionizing mental healthcare through next-generation psychedelic-derived therapies. Founded in 2019 and operating in Canada, the United States, the United Kingdom and Ireland, the company is developing a pipeline that includes CYB003, now in Phase 3 trials as an adjunctive treatment for major depressive disorder with Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and CYB004 in a Phase 2 study for generalized anxiety disorder, alongside an extensive research portfolio of investigational compounds.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.92M
For an in-depth examination of CYBN stock, go to TipRanks’ Overview page.